Sarepta’s surprise FDA approval for rare disease drug excites investors
December 13, 2019 at 12:22 PM EST
The Food and Drug Administration’s out-of-the-blue approval of Sarepta Therapeutics’ second Duchenne muscular dystrophy drug sent the company’s stock soaring.